Side Effects of Dabrafenib and Trametinib Combination Therapy

Introduction to Side Effects

• The combination of dabrafenib and trametinib causes predominantly flu-like symptoms, gastrointestinal upset, and skin toxicities, but importantly reduces the hyperproliferative skin lesions seen with BRAF inhibitor monotherapy 1, 2

Most Common Side Effects

• Pyrexia occurs in approximately 50% of patients and is significantly more common with combination therapy than monotherapy 1, 2
• Chills affect a substantial proportion of patients 1, 2
• Fatigue and asthenia are very common, affecting 38-52% of patients 1, 2
• Headache occurs frequently 1, 2
• Diarrhea is notably more common with BRAF/MEK combination than BRAF monotherapy 1, 2
• Nausea affects 35-52% of patients 1, 2
• Vomiting occurs in a significant subset of patients 1, 2
• Decreased appetite is a common side effect 1, 2
• Rash is common with combination therapy 1, 2
• Alopecia affects approximately 36% of patients 1, 2
• Arthralgia is less common with combination therapy compared to BRAF monotherapy 1, 2
• Myalgia is similarly reduced with combination versus monotherapy 1, 2
• Patients should be educated to report joint pain and swelling 3, 4
• Hypertension occurs in 6-14% of patients 1, 2
• Elevated liver enzymes occur in 1-15% of patients, depending on grade 1, 2
• Elevated CPK, alkaline phosphatase, and lipase are common laboratory abnormalities 1, 2
• Anemia is a common side effect 1, 2

Critical Advantage: Reduced Hyperproliferative Skin Toxicities

• A key benefit of combination therapy is the dramatic reduction in dangerous hyperproliferative skin lesions compared to BRAF inhibitor monotherapy 1, 2
• Cutaneous squamous cell carcinoma is markedly reduced with combination therapy 1, 2
• Keratoacanthoma has a substantially lower incidence with combination therapy 1, 2
• Hyperkeratosis is less common with combination therapy 1, 2
• Palmoplantar disorders have a reduced frequency with combination therapy 1, 2

Serious but Rare Toxicities

• Serous retinopathy is the most notable ocular toxicity, specifically from trametinib 5
• Mandatory ophthalmologic surveillance protocol is recommended, including comprehensive dilated fundoscopy at baseline, recheck at 2-3 weeks, and every 3-4 months during the first year of treatment 5
• Decreased ejection fraction is a serious adverse event reported 6
• Deep venous thrombosis is a rare event attributed to MEK inhibitors 1, 2
• Neutropenia, hyponatremia, hemoptysis, and intracranial hemorrhage are rare but serious events 6

Clinical Management Pearls

• Regular skin evaluation and dermatology referral are still recommended despite reduced risk, as secondary skin lesions remain a class effect of BRAF inhibition 3, 7, 4
• The shift from BRAF monotherapy to BRAF/MEK combinations has resulted in lower discontinuation rates due to hyperproliferative skin toxicities and musculoskeletal complaints 1, 2
• Flu-like symptoms are less likely to lead to treatment discontinuation, especially when patients are forewarned 1, 2
• Most adverse events are mild and do not require discontinuation 3, 7, 4

Overall Toxicity Profile

• All-grade adverse events occur in 97-99% of patients 1, 2
• Grade 3-5 adverse events occur in 48-50% of patients with combination therapy, similar to monotherapy 1, 2
• The overall risk of toxicity is similar between combination and monotherapy, but the type of toxicities differs significantly 1, 2

Adverse Effects and Management of Dabrafenib + Trametinib Combination Therapy

Constitutional (Flu‑Like) Symptoms

• Fever (pyrexia) occurs in roughly half of treated patients and is often grade 3 (≈6%). The NCCN recommends managing fever with acetaminophen and/or NSAIDs and, if necessary, a temporary drug hold. 8
• Chills are reported in about 92 % of patients receiving neoadjuvant dabrafenib + trametinib. [9][10]
• Headache is reported in about 92 % of patients in the same neoadjuvant setting. [9][10]

Gastrointestinal Toxicity

• Grade 3 diarrhea occurs in approximately 15 % of patients in neoadjuvant trials of the combination. [9][10]

Dermatologic Monitoring

• Regular skin examinations and referral to dermatology are advised despite the lower incidence of secondary skin lesions with the combination. This reflects the persistent class‑effect of BRAF inhibition. 8
• Keratoacanthoma incidence is markedly lower with combination therapy; the reference rate is 6 % with dabrafenib monotherapy. 8

Musculoskeletal Safety Counseling

• Patients should be instructed to promptly report any joint pain or swelling while on therapy. 8

Overall Toxicity Profile

• Most adverse events are mild and do not require treatment discontinuation. The NCCN notes that the majority of AEs are manageable without stopping therapy. 8

Treatment Discontinuation Rates

• In the COMBI‑AD trial, 26 % of patients discontinued dabrafenib + trametinib, which is higher than the 8‑10 % discontinuation observed with anti‑PD‑1 therapy. 11

Alternative BRAF/MEK Regimens

• When dabrafenib + trametinib toxicity is unacceptable, alternative BRAF/MEK combinations (e.g., vemurafenib + cobimetinib or encorafenib + binimetinib) may be considered. This recommendation is supported by NCCN guidance. 9